Categories
Change Password!
Reset Password!
Commencing Teduglutide therapy at an early age correlates with increased response rates.
Marta German Diaz's study, published in the European Journal of Pediatrics revealed Teduglutide to be a safe and effective treatment for pediatric intestinal failure (IF), reducing the need for parenteral support.
This national multicenter prospective study involved children with IF treated with Teduglutide for a minimum of 3 months. Thirty-one patients had a median age of 2.3 years at the start of treatment.
Short bowel syndrome (SBS) was the leading cause of IF (94%), primarily attributed to necrotizing enterocolitis (35%). The median duration of Teduglutide therapy was 19 months, with 74% of patients treated for over 1 year and 29% for over 3 years. The response of the therapy was estimated in 30 patients.
Results showed that 24 patients (80%) experienced more than a 20% reduction in their weekly parenteral nutrition (PN) energy, and 23 patients (77%) saw a similar reduction in their weekly PN volume. Among responders, 9 patients (29%) were successfully weaned off PN, with a median treatment duration of 6 months and younger patients at the beginning of treatment were more likely to achieve a substantial decrease in the amount of parenteral nutrition they required every week. However, some patients with IF require extended Teduglutide to accomplish enteral autonomy.
European Journal of Pediatrics
Early use of Teduglutide in paediatric patients with intestinal failure is associated with a greater response rate: a multicenter study
Marta German Diaz et al.
Comments (0)